Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Unisys Research on Trustworthy AI Published in Frontiers in Pharmacology Journal
BLUE BELL, Pennsylvania, Sept. 4 (TNSjou) -- Unisys, a technology solutions company, issued the following news release:
* * *
Unisys Research on Trustworthy AI Published in Frontiers in Pharmacology Journal
Peer-reviewed study explores how neurosymbolic AI can improve trust and explainability with emerging technologies in healthcare and other regulated industries
-
Unisys (NYSE: UIS) announces the publication of its peer-reviewed research paper, "From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing," ... Show Full Article BLUE BELL, Pennsylvania, Sept. 4 (TNSjou) -- Unisys, a technology solutions company, issued the following news release: * * * Unisys Research on Trustworthy AI Published in Frontiers in Pharmacology Journal Peer-reviewed study explores how neurosymbolic AI can improve trust and explainability with emerging technologies in healthcare and other regulated industries - Unisys (NYSE: UIS) announces the publication of its peer-reviewed research paper, "From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing,"in Frontiers in Pharmacology, a leading journal from Frontiers Media. The study explores one of the most significant barriers to AI adoption in healthcare and other regulated industries: the need for clear visibility into how AI systems generate recommendations to validate and trust their outputs.
Many AI systems can generate outputs but cannot clearly explain how they arrived at them, making it difficult for organizations to evaluate and trust the results. To address this challenge, the research explores a neurosymbolic AI approach that combines advanced AI techniques with human knowledge and reasoning to provide greater transparency into how conclusions are reached.
The paper also introduces a new framework, called MURP (Mechanistic Coherence, Uncertainty, Robustness and Provenance), which extends the evaluation of AI systems beyond predictive accuracy to include criteria needed for use in highly regulated environments.
The next phase of AI innovation will be shaped not only by performance, but by credibility," said Salvatore Sinno, vice president of innovation, Enterprise Computing Solutions, Unisys. "Organizations are increasingly exploring AI in complex and regulated settings, making the ability to evaluate, govern and stand behind AI-driven outcomes just as important as the outcomes themselves."
This publication further demonstrates how Unisys is advancing AI research that turns emerging capabilities into practical business value. Together with findings from the recently published Unisys AI & Cloud Insights Report 2026, this work supports the company's AI-First strategy and focuses on moving organizations from experimentation to scalable, real-world adoption.
Read the published research paper (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1860953/full) in Frontiers in Pharmacology and learn more about AI offerings (https://www.unisys.com/solutions/artificial-intelligence/) from Unisys.
* * *
About Unisys
Unisys is a global technology solutions company that powers breakthroughs for the world's leading organizations. Our solutions - cloud, AI, digital workplace, applications and enterprise computing - help our clients challenge the status quo and unlock their full potential. To learn how we have been helping clients push what's possible for more than 150 years, visit unisys.com and follow us on LinkedIn.
* * *
Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.
* * *
Original text here: https://www.unisys.com/news-release/unisys-research-on-trustworthy-ai-published-in-frontiers-in-pharmacology-journal/
[Category: BizComputer Technology]
* * *
Unisys Research on Trustworthy AI Published in Frontiers in Pharmacology Journal
Peer-reviewed study explores how neurosymbolic AI can improve trust and explainability with emerging technologies in healthcare and other regulated industries
-
Unisys (NYSE: UIS) announces the publication of its peer-reviewed research paper, "From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing," ... Show Full Article BLUE BELL, Pennsylvania, Sept. 4 (TNSjou) -- Unisys, a technology solutions company, issued the following news release: * * * Unisys Research on Trustworthy AI Published in Frontiers in Pharmacology Journal Peer-reviewed study explores how neurosymbolic AI can improve trust and explainability with emerging technologies in healthcare and other regulated industries - Unisys (NYSE: UIS) announces the publication of its peer-reviewed research paper, "From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing,"in Frontiers in Pharmacology, a leading journal from Frontiers Media. The study explores one of the most significant barriers to AI adoption in healthcare and other regulated industries: the need for clear visibility into how AI systems generate recommendations to validate and trust their outputs.
Many AI systems can generate outputs but cannot clearly explain how they arrived at them, making it difficult for organizations to evaluate and trust the results. To address this challenge, the research explores a neurosymbolic AI approach that combines advanced AI techniques with human knowledge and reasoning to provide greater transparency into how conclusions are reached.
The paper also introduces a new framework, called MURP (Mechanistic Coherence, Uncertainty, Robustness and Provenance), which extends the evaluation of AI systems beyond predictive accuracy to include criteria needed for use in highly regulated environments.
The next phase of AI innovation will be shaped not only by performance, but by credibility," said Salvatore Sinno, vice president of innovation, Enterprise Computing Solutions, Unisys. "Organizations are increasingly exploring AI in complex and regulated settings, making the ability to evaluate, govern and stand behind AI-driven outcomes just as important as the outcomes themselves."
This publication further demonstrates how Unisys is advancing AI research that turns emerging capabilities into practical business value. Together with findings from the recently published Unisys AI & Cloud Insights Report 2026, this work supports the company's AI-First strategy and focuses on moving organizations from experimentation to scalable, real-world adoption.
Read the published research paper (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1860953/full) in Frontiers in Pharmacology and learn more about AI offerings (https://www.unisys.com/solutions/artificial-intelligence/) from Unisys.
* * *
About Unisys
Unisys is a global technology solutions company that powers breakthroughs for the world's leading organizations. Our solutions - cloud, AI, digital workplace, applications and enterprise computing - help our clients challenge the status quo and unlock their full potential. To learn how we have been helping clients push what's possible for more than 150 years, visit unisys.com and follow us on LinkedIn.
* * *
Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.
* * *
Original text here: https://www.unisys.com/news-release/unisys-research-on-trustworthy-ai-published-in-frontiers-in-pharmacology-journal/
[Category: BizComputer Technology]
Studsvik, GE Vernova Hitachi and Samsung C&T Commit to Advancing 1.2 GW Nuclear Power Project in Sweden
CAMBRIDGE, Massachusetts, Sept. 4 -- G.E. Vernova, an energy company, posted the following news release on Sept. 3, 2026:
* * *
Studsvik, GE Vernova Hitachi and Samsung C&T commit to advancing 1.2 GW nuclear power project in Sweden
Following a competitive evaluation process, Studsvik has selected GE Vernova Hitachi Nuclear Energy and Samsung C&T as its strategic collaborators for its first nuclear project in Sweden, planned for either at its existing licensed site in Nykoping or the Malma site in Valdemarsvik.
Together with GE Vernova's Financial Services business and DS Investment Partners, ... Show Full Article CAMBRIDGE, Massachusetts, Sept. 4 -- G.E. Vernova, an energy company, posted the following news release on Sept. 3, 2026: * * * Studsvik, GE Vernova Hitachi and Samsung C&T commit to advancing 1.2 GW nuclear power project in Sweden Following a competitive evaluation process, Studsvik has selected GE Vernova Hitachi Nuclear Energy and Samsung C&T as its strategic collaborators for its first nuclear project in Sweden, planned for either at its existing licensed site in Nykoping or the Malma site in Valdemarsvik. Together with GE Vernova's Financial Services business and DS Investment Partners,the companies will advance an initial four-unit BWRX-300 project in Sweden with 1.2 GW of nuclear capacity. The first unit expected to enter operation in the mid-2030s.
NYKOPING, Sweden - Studsvik AB (publ), GE Vernova Hitachi Nuclear Energy, GE Vernova's Financial Services business, DS Investment Partners and Samsung C&T today announced an agreement to advance the ReFirm nuclear program at Studsvik's sites in Sweden. The agreement is exclusive for a fixed period, which the parties may extend.
ReFirm is Studsvik's multi-site small modular reactor (SMR) and new nuclear program, added through its acquisition of Karnfull Next (KNXT) earlier this year. KNXT has worked with GE Vernova Hitachi on BWRX-300 deployment in Sweden since 2022 and entered into a strategic teaming agreement with Samsung C&T in December 2024. Today's announcement advances plans for the Nykoping and Valdemarsvik sites, with an initial four-unit BWRX-300 project totaling approximately 1,200 MWe planned for one of the two locations.
At Nykoping, Studsvik operates an existing licensed nuclear facility. At Valdemarsvik, an application was submitted in March 2026, the first made under Sweden's new legislation requiring government approval for nuclear facilities. Which site hosts the first project will be decided during the development work.
The phased, multi-unit structure is intended to support standardization across the program and creates opportunities to capture lessons learned from early deployment and apply them to subsequent units, helping improve cost, schedule and productivity outcomes.
It will also help increase Swedish industrial participation throughout engineering, procurement, construction, and long-term operations. This reflects the broader objective of building a supply chain that can help support not only the first project, but also follow-on units and wider deployment opportunities in Sweden and Europe.
The agreement marks the next phase of development and does not constitute a final investment decision or authorization to construct. The parties will begin joint development work immediately, including commercial, technical, regulatory and financing activities during the exclusivity period.
Studsvik leads permitting, the environmental impact assessment, site rights, community engagement and the dialogue with the Swedish state. GE Vernova Hitachi leads reactor engineering, licensing support and cost estimation and acts as engineering authority, and, together with Samsung C&T, acts as the execution team, giving the project single-point responsibility for construction and execution. During the exclusivity period, DS Investment Partners, a South Korean investment firm, will lead the investment and GE Vernova's Financial Services business will participate in an advisory and financial structuring capacity in support of the consortium.
A project company will be established to support development, financing, construction, ownership and operation of the plants, with details to be finalized in definitive agreements.
Sweden is expanding nuclear capacity under legislation in force since 2026 that permits reactors at sites beyond the three existing plants and requires government approval for each, supported by a state financing framework of loans and two-way contracts for difference.
"Sweden's electricity supply is a long-term play: existing nuclear capacity is ageing, and demand for baseload power is growing. To meet that, we have looked for long-term partners and for the conditions that let projects like this succeed. In GE Vernova Hitachi and Samsung C&T we have found them. We intend to build the first project either on an existing nuclear site or on greenfield. One plant is a project. Four is the start of an industry."
Karl Thedeen, President and Chief Executive Officer, Studsvik
"Today's announcement is about helping Sweden turn its energy ambitions into reality in a timeframe that matters for its communities and industries. The country has a strong foundation of nuclear expertise and operational excellence, and the BWRX-300 combines boiling water reactor technology with the lessons being learned every day at the Darlington New Nuclear Project in Canada. Together with a growing global pipeline of projects across North America and Europe, this experience gives Sweden access to a technology that is moving from first-of-a-kind deployment toward fleet-scale execution."
Jason Cooper, Chief Executive Officer, GE Vernova Hitachi Nuclear Energy
"Samsung C&T is honored to partner with Studsvik, GE Vernova Hitachi and the other members of the development team to support Sweden's next generation of nuclear energy. By combining proven technology, world-class EPC execution, operational excellence and financing capability, we are establishing a strong foundation for the successful development of the ReFirm program. We are equally committed to strengthening Sweden's industrial capability, expanding local supply chains and building a long-term strategic partnership that creates lasting value for Studsvik and Sweden."
Oh Se-chul, President and Chief Executive Officer, Engineering & Construction Group, Samsung C&T
* * *
Notes to editors: Signing ceremony photograph names (left to right): Jason Cooper, Oh Se-chul, Karl Thedeen, Seung Su Kang, Leo Fortey
About Studsvik
Studsvik is an independent nuclear technology company active across the full nuclear lifecycle, from new build development to existing fleet services, operations support and decommissioning. Its reactor analysis software is used at more than half of the world's commercial reactors, and its hot cell laboratories in Nykoping test fuel and materials for fission and fusion applications worldwide. Studsvik also provides radiation protection services and technology for treating radioactive waste, and handles and packages radioisotopes for healthcare and industry. ReFirm is Studsvik's platform for new nuclear development in Sweden. Founded in 1947 as the center of Sweden's national nuclear program, Studsvik today serves operators, fuel vendors, technology developers and regulators in more than 20 countries, has approximately 540 employees in six countries, and is listed on Nasdaq Stockholm (SVIK).
* * *
About Samsung C&T
Samsung C&T's Engineering & Construction Group has more than 40 years of engineering and construction experience operating throughout the world. The group spans commercial and residential buildings, civil infrastructure and plant construction. Its landmark projects include Burj Khalifa, the world's tallest building, the ongoing Riyadh Metro Project in Saudi Arabia, the Qurayyah 4,000MW CCPP Project, and the ongoing Qatar 2,000MW Solar Power Project. In the nuclear energy sector, the company has successfully delivered 12GW across 10 units, including the 5.6GW Barakah Nuclear Power Plant in the UAE. It has recently undertaken the Nuclear Power Plant refurbishment project and Front-End Engineering Design (FEED) for Small Modular Reactors (SMRs), demonstrating its global competitiveness in large-scale reactor and SMR technologies, and solidifying its expertise across all areas of the nuclear industry.
* * *
About GE Vernova Hitachi Nuclear Energy
GE Vernova's Nuclear energy business, through its global alliance with Hitachi, is a world-leading provider of nuclear fuel bundles, services, and advanced nuclear reactor designs. Technologies include boiling water reactors and small modular reactors, such as the BWRX-300, which is one of the simplest, yet most innovative boiling water reactor designs. GE Vernova's Nuclear fuel business, Global Nuclear Fuel (GNF), is a world-leading supplier of boiling water reactor fuel and fuel-related engineering services. GNF is a GE Vernova-led joint venture with Hitachi, Ltd. and operates primarily through Global Nuclear Fuel-Americas, LLC in Wilmington, N.C., and Global Nuclear Fuel-Japan Co., Ltd. in Kurihama, Japan. HITACHI is a trademark of Hitachi, Ltd. used under trademark license. GE is a trademark of General Electric Company used under trademark license.
* * *
Forward-Looking Statements
This document contains forward-looking statements - that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. These forward-looking statements often address GE Vernova's expected future business and financial performance and financial condition, and the expected performance of its products, the impact of its services and the results they may generate or produce, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "estimate," "forecast," "target," "preliminary," or "range." Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about planned and potential transactions, investments or projects and their expected results and the impacts of macroeconomic and market conditions and volatility on the Company's business operations, financial results and financial position and on the global supply chain and world economy.
* * *
Original text here: https://www.gevernova.com/news/press-releases/studsvik-ge-vernova-hitachi-samsung-ct-commit-advancing-12-gw-nuclear-power-project
[Category: BizEnergy]
* * *
Studsvik, GE Vernova Hitachi and Samsung C&T commit to advancing 1.2 GW nuclear power project in Sweden
Following a competitive evaluation process, Studsvik has selected GE Vernova Hitachi Nuclear Energy and Samsung C&T as its strategic collaborators for its first nuclear project in Sweden, planned for either at its existing licensed site in Nykoping or the Malma site in Valdemarsvik.
Together with GE Vernova's Financial Services business and DS Investment Partners, ... Show Full Article CAMBRIDGE, Massachusetts, Sept. 4 -- G.E. Vernova, an energy company, posted the following news release on Sept. 3, 2026: * * * Studsvik, GE Vernova Hitachi and Samsung C&T commit to advancing 1.2 GW nuclear power project in Sweden Following a competitive evaluation process, Studsvik has selected GE Vernova Hitachi Nuclear Energy and Samsung C&T as its strategic collaborators for its first nuclear project in Sweden, planned for either at its existing licensed site in Nykoping or the Malma site in Valdemarsvik. Together with GE Vernova's Financial Services business and DS Investment Partners,the companies will advance an initial four-unit BWRX-300 project in Sweden with 1.2 GW of nuclear capacity. The first unit expected to enter operation in the mid-2030s.
NYKOPING, Sweden - Studsvik AB (publ), GE Vernova Hitachi Nuclear Energy, GE Vernova's Financial Services business, DS Investment Partners and Samsung C&T today announced an agreement to advance the ReFirm nuclear program at Studsvik's sites in Sweden. The agreement is exclusive for a fixed period, which the parties may extend.
ReFirm is Studsvik's multi-site small modular reactor (SMR) and new nuclear program, added through its acquisition of Karnfull Next (KNXT) earlier this year. KNXT has worked with GE Vernova Hitachi on BWRX-300 deployment in Sweden since 2022 and entered into a strategic teaming agreement with Samsung C&T in December 2024. Today's announcement advances plans for the Nykoping and Valdemarsvik sites, with an initial four-unit BWRX-300 project totaling approximately 1,200 MWe planned for one of the two locations.
At Nykoping, Studsvik operates an existing licensed nuclear facility. At Valdemarsvik, an application was submitted in March 2026, the first made under Sweden's new legislation requiring government approval for nuclear facilities. Which site hosts the first project will be decided during the development work.
The phased, multi-unit structure is intended to support standardization across the program and creates opportunities to capture lessons learned from early deployment and apply them to subsequent units, helping improve cost, schedule and productivity outcomes.
It will also help increase Swedish industrial participation throughout engineering, procurement, construction, and long-term operations. This reflects the broader objective of building a supply chain that can help support not only the first project, but also follow-on units and wider deployment opportunities in Sweden and Europe.
The agreement marks the next phase of development and does not constitute a final investment decision or authorization to construct. The parties will begin joint development work immediately, including commercial, technical, regulatory and financing activities during the exclusivity period.
Studsvik leads permitting, the environmental impact assessment, site rights, community engagement and the dialogue with the Swedish state. GE Vernova Hitachi leads reactor engineering, licensing support and cost estimation and acts as engineering authority, and, together with Samsung C&T, acts as the execution team, giving the project single-point responsibility for construction and execution. During the exclusivity period, DS Investment Partners, a South Korean investment firm, will lead the investment and GE Vernova's Financial Services business will participate in an advisory and financial structuring capacity in support of the consortium.
A project company will be established to support development, financing, construction, ownership and operation of the plants, with details to be finalized in definitive agreements.
Sweden is expanding nuclear capacity under legislation in force since 2026 that permits reactors at sites beyond the three existing plants and requires government approval for each, supported by a state financing framework of loans and two-way contracts for difference.
"Sweden's electricity supply is a long-term play: existing nuclear capacity is ageing, and demand for baseload power is growing. To meet that, we have looked for long-term partners and for the conditions that let projects like this succeed. In GE Vernova Hitachi and Samsung C&T we have found them. We intend to build the first project either on an existing nuclear site or on greenfield. One plant is a project. Four is the start of an industry."
Karl Thedeen, President and Chief Executive Officer, Studsvik
"Today's announcement is about helping Sweden turn its energy ambitions into reality in a timeframe that matters for its communities and industries. The country has a strong foundation of nuclear expertise and operational excellence, and the BWRX-300 combines boiling water reactor technology with the lessons being learned every day at the Darlington New Nuclear Project in Canada. Together with a growing global pipeline of projects across North America and Europe, this experience gives Sweden access to a technology that is moving from first-of-a-kind deployment toward fleet-scale execution."
Jason Cooper, Chief Executive Officer, GE Vernova Hitachi Nuclear Energy
"Samsung C&T is honored to partner with Studsvik, GE Vernova Hitachi and the other members of the development team to support Sweden's next generation of nuclear energy. By combining proven technology, world-class EPC execution, operational excellence and financing capability, we are establishing a strong foundation for the successful development of the ReFirm program. We are equally committed to strengthening Sweden's industrial capability, expanding local supply chains and building a long-term strategic partnership that creates lasting value for Studsvik and Sweden."
Oh Se-chul, President and Chief Executive Officer, Engineering & Construction Group, Samsung C&T
* * *
Notes to editors: Signing ceremony photograph names (left to right): Jason Cooper, Oh Se-chul, Karl Thedeen, Seung Su Kang, Leo Fortey
About Studsvik
Studsvik is an independent nuclear technology company active across the full nuclear lifecycle, from new build development to existing fleet services, operations support and decommissioning. Its reactor analysis software is used at more than half of the world's commercial reactors, and its hot cell laboratories in Nykoping test fuel and materials for fission and fusion applications worldwide. Studsvik also provides radiation protection services and technology for treating radioactive waste, and handles and packages radioisotopes for healthcare and industry. ReFirm is Studsvik's platform for new nuclear development in Sweden. Founded in 1947 as the center of Sweden's national nuclear program, Studsvik today serves operators, fuel vendors, technology developers and regulators in more than 20 countries, has approximately 540 employees in six countries, and is listed on Nasdaq Stockholm (SVIK).
* * *
About Samsung C&T
Samsung C&T's Engineering & Construction Group has more than 40 years of engineering and construction experience operating throughout the world. The group spans commercial and residential buildings, civil infrastructure and plant construction. Its landmark projects include Burj Khalifa, the world's tallest building, the ongoing Riyadh Metro Project in Saudi Arabia, the Qurayyah 4,000MW CCPP Project, and the ongoing Qatar 2,000MW Solar Power Project. In the nuclear energy sector, the company has successfully delivered 12GW across 10 units, including the 5.6GW Barakah Nuclear Power Plant in the UAE. It has recently undertaken the Nuclear Power Plant refurbishment project and Front-End Engineering Design (FEED) for Small Modular Reactors (SMRs), demonstrating its global competitiveness in large-scale reactor and SMR technologies, and solidifying its expertise across all areas of the nuclear industry.
* * *
About GE Vernova Hitachi Nuclear Energy
GE Vernova's Nuclear energy business, through its global alliance with Hitachi, is a world-leading provider of nuclear fuel bundles, services, and advanced nuclear reactor designs. Technologies include boiling water reactors and small modular reactors, such as the BWRX-300, which is one of the simplest, yet most innovative boiling water reactor designs. GE Vernova's Nuclear fuel business, Global Nuclear Fuel (GNF), is a world-leading supplier of boiling water reactor fuel and fuel-related engineering services. GNF is a GE Vernova-led joint venture with Hitachi, Ltd. and operates primarily through Global Nuclear Fuel-Americas, LLC in Wilmington, N.C., and Global Nuclear Fuel-Japan Co., Ltd. in Kurihama, Japan. HITACHI is a trademark of Hitachi, Ltd. used under trademark license. GE is a trademark of General Electric Company used under trademark license.
* * *
Forward-Looking Statements
This document contains forward-looking statements - that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. These forward-looking statements often address GE Vernova's expected future business and financial performance and financial condition, and the expected performance of its products, the impact of its services and the results they may generate or produce, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "estimate," "forecast," "target," "preliminary," or "range." Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about planned and potential transactions, investments or projects and their expected results and the impacts of macroeconomic and market conditions and volatility on the Company's business operations, financial results and financial position and on the global supply chain and world economy.
* * *
Original text here: https://www.gevernova.com/news/press-releases/studsvik-ge-vernova-hitachi-samsung-ct-commit-advancing-12-gw-nuclear-power-project
[Category: BizEnergy]
Nuclear Medicine Physician-scientist Dr. Amir Iravani Joins UCLA Health to Lead Theranostics Program
LOS ANGELES, California, Sept. 4 -- The UCLA Health issued the following news release:
* * *
Nuclear medicine physician-scientist Dr. Amir Iravani joins UCLA Health to lead Theranostics Program
Dr. Iravani brings expertise in molecular imaging and radiopharmaceutical therapy to help expand research and clinical cancer care
-
Dr. Amir Iravani, a nationally recognized nuclear medicine physician-scientist specializing in molecular imaging and targeted radiopharmaceutical therapies for patients with cancer, has joined UCLA Health where he will serve as director of the Theranostics Program and ... Show Full Article LOS ANGELES, California, Sept. 4 -- The UCLA Health issued the following news release: * * * Nuclear medicine physician-scientist Dr. Amir Iravani joins UCLA Health to lead Theranostics Program Dr. Iravani brings expertise in molecular imaging and radiopharmaceutical therapy to help expand research and clinical cancer care - Dr. Amir Iravani, a nationally recognized nuclear medicine physician-scientist specializing in molecular imaging and targeted radiopharmaceutical therapies for patients with cancer, has joined UCLA Health where he will serve as director of the Theranostics Program andvice chair of clinical research in the department of nuclear medicine and theranostics.
In his new roles, Iravani will work with colleagues across the health system, including the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center, to advance the integration of theranostics into cancer care, expand clinical trials and research opportunities and develop new collaborations in precision health.
"I have followed UCLA's leadership in radiopharmaceutical therapy and molecular imaging for many years, so this opportunity was very consistent with what I wanted to do at the next stage of my career," said Iravani. "The establishment of an independent department of nuclear medicine and theranostics makes this an especially exciting time to join UCLA and help advance the field."
Iravani brings extensive experience in theranostics, having trained at the Peter MacCallum Cancer Centre in Melbourne, Australia, a world-leading center in the field. More recently, he served as theranostics clinical director at Fred Hutchinson Cancer Center in Seattle and was an associate professor of radiology at the University of Washington School of Medicine, where he helped advance clinical care and research in molecular imaging and theranostics.
Iravani has a distinguished record of research in molecular imaging and radiopharmaceutical therapy, with a focus on developing more personalized approaches to cancer treatment. His work spans across various malignancies, including neuroendocrine tumors, prostate cancer, and thyroid cancer. He studies how imaging biomarkers can be used to identify patients most likely to benefit from targeted therapies, optimize treatment schedules and monitor how tumors respond to treatment.
His research has included the use of prostate-specific membrane antigen, or PSMA, imaging to guide radiopharmaceutical therapy for prostate cancer. PSMA PET imaging allows physicians to visualize the presence and distribution of PSMA-expressing prostate cancer throughout the body and can help identify patients who may benefit from PSMA-targeted therapies.
More recently, Iravani has focused on further personalizing radiopharmaceutical therapy by using quantitative information from imaging, along with other biomarkers such as liquid biopsies, to determine the most appropriate dose and timing of treatment for individual patients.
Iravani's vision for the UCLA program includes expanding theranostics beyond its current applications in prostate cancer and neuroendocrine tumors. He plans to help bring novel radiopharmaceutical therapies into clinical trials at UCLA and explore opportunities to develop treatment options for patients with additional solid tumors and hematologic malignancies.
"The next step is integrating theranostics more fully into cancer care and expanding it beyond the diseases where we currently have approved treatments," said Iravani. "There are many novel agents in development, and I hope we can bring more of these early clinical trials to UCLA and give patients access to promising new treatments."
The expansion will build on UCLA's longstanding leadership in molecular imaging and radiopharmaceutical therapy. The department of nuclear medicine and theranostics, which became an independent department in 2026, brings together clinical care, translational research, radiochemistry, preclinical research and clinical trials to accelerate the development of new diagnostic and therapeutic approaches.
"Dr. Iravani brings a unique combination of clinical expertise and research innovation that will further strengthen UCLA's leadership in theranostics," said Dr. Johannes Czernin, acting chair of the department of nuclear medicine and theranostics. "His experience in developing personalized treatment strategies and conducting clinical research will help us expand the impact of this field and bring new options to our patients."
UCLA has been a leader in advancing theranostics from discovery to patient care. Over the past decade, UCLA physician-scientists have pioneered advances in PSMA PET imaging and radiopharmaceutical therapy, including research that helped establish PSMA PET as an important tool for detecting prostate cancer throughout the body and supported the development of targeted radiopharmaceutical therapies now used to treat patients with advanced disease.
For Iravani, the ultimate goal of advancing theranostics is to improve the lives of patients.
"My major motivation is seeing patients benefit from the interventions we develop -- improving their quality of life and, hopefully, their longevity," said Iravani. "I'm excited to work in a vibrant, collaborative environment where we can bring together people with the same goal of improving outcomes for patients."
* * *
Original text here: https://www.uclahealth.org/news/release/nuclear-medicine-physician-scientist-dr-amir-iravani-joins
[Category: Medical]
* * *
Nuclear medicine physician-scientist Dr. Amir Iravani joins UCLA Health to lead Theranostics Program
Dr. Iravani brings expertise in molecular imaging and radiopharmaceutical therapy to help expand research and clinical cancer care
-
Dr. Amir Iravani, a nationally recognized nuclear medicine physician-scientist specializing in molecular imaging and targeted radiopharmaceutical therapies for patients with cancer, has joined UCLA Health where he will serve as director of the Theranostics Program and ... Show Full Article LOS ANGELES, California, Sept. 4 -- The UCLA Health issued the following news release: * * * Nuclear medicine physician-scientist Dr. Amir Iravani joins UCLA Health to lead Theranostics Program Dr. Iravani brings expertise in molecular imaging and radiopharmaceutical therapy to help expand research and clinical cancer care - Dr. Amir Iravani, a nationally recognized nuclear medicine physician-scientist specializing in molecular imaging and targeted radiopharmaceutical therapies for patients with cancer, has joined UCLA Health where he will serve as director of the Theranostics Program andvice chair of clinical research in the department of nuclear medicine and theranostics.
In his new roles, Iravani will work with colleagues across the health system, including the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center, to advance the integration of theranostics into cancer care, expand clinical trials and research opportunities and develop new collaborations in precision health.
"I have followed UCLA's leadership in radiopharmaceutical therapy and molecular imaging for many years, so this opportunity was very consistent with what I wanted to do at the next stage of my career," said Iravani. "The establishment of an independent department of nuclear medicine and theranostics makes this an especially exciting time to join UCLA and help advance the field."
Iravani brings extensive experience in theranostics, having trained at the Peter MacCallum Cancer Centre in Melbourne, Australia, a world-leading center in the field. More recently, he served as theranostics clinical director at Fred Hutchinson Cancer Center in Seattle and was an associate professor of radiology at the University of Washington School of Medicine, where he helped advance clinical care and research in molecular imaging and theranostics.
Iravani has a distinguished record of research in molecular imaging and radiopharmaceutical therapy, with a focus on developing more personalized approaches to cancer treatment. His work spans across various malignancies, including neuroendocrine tumors, prostate cancer, and thyroid cancer. He studies how imaging biomarkers can be used to identify patients most likely to benefit from targeted therapies, optimize treatment schedules and monitor how tumors respond to treatment.
His research has included the use of prostate-specific membrane antigen, or PSMA, imaging to guide radiopharmaceutical therapy for prostate cancer. PSMA PET imaging allows physicians to visualize the presence and distribution of PSMA-expressing prostate cancer throughout the body and can help identify patients who may benefit from PSMA-targeted therapies.
More recently, Iravani has focused on further personalizing radiopharmaceutical therapy by using quantitative information from imaging, along with other biomarkers such as liquid biopsies, to determine the most appropriate dose and timing of treatment for individual patients.
Iravani's vision for the UCLA program includes expanding theranostics beyond its current applications in prostate cancer and neuroendocrine tumors. He plans to help bring novel radiopharmaceutical therapies into clinical trials at UCLA and explore opportunities to develop treatment options for patients with additional solid tumors and hematologic malignancies.
"The next step is integrating theranostics more fully into cancer care and expanding it beyond the diseases where we currently have approved treatments," said Iravani. "There are many novel agents in development, and I hope we can bring more of these early clinical trials to UCLA and give patients access to promising new treatments."
The expansion will build on UCLA's longstanding leadership in molecular imaging and radiopharmaceutical therapy. The department of nuclear medicine and theranostics, which became an independent department in 2026, brings together clinical care, translational research, radiochemistry, preclinical research and clinical trials to accelerate the development of new diagnostic and therapeutic approaches.
"Dr. Iravani brings a unique combination of clinical expertise and research innovation that will further strengthen UCLA's leadership in theranostics," said Dr. Johannes Czernin, acting chair of the department of nuclear medicine and theranostics. "His experience in developing personalized treatment strategies and conducting clinical research will help us expand the impact of this field and bring new options to our patients."
UCLA has been a leader in advancing theranostics from discovery to patient care. Over the past decade, UCLA physician-scientists have pioneered advances in PSMA PET imaging and radiopharmaceutical therapy, including research that helped establish PSMA PET as an important tool for detecting prostate cancer throughout the body and supported the development of targeted radiopharmaceutical therapies now used to treat patients with advanced disease.
For Iravani, the ultimate goal of advancing theranostics is to improve the lives of patients.
"My major motivation is seeing patients benefit from the interventions we develop -- improving their quality of life and, hopefully, their longevity," said Iravani. "I'm excited to work in a vibrant, collaborative environment where we can bring together people with the same goal of improving outcomes for patients."
* * *
Original text here: https://www.uclahealth.org/news/release/nuclear-medicine-physician-scientist-dr-amir-iravani-joins
[Category: Medical]
Houlihan Lokey Continues to Expand European Financial Sponsors Coverage Team With Senior Hire in France
LOS ANGELES, California, Sept. 4 [Category: BizFinancial Services] -- Houlihan Lokey, an investment bank, issued the following news release:
* * *
Houlihan Lokey Continues to Expand European Financial Sponsors Coverage Team With Senior Hire in France
Jean-Baptiste Didier Joins as a Managing Director in the Financial Sponsors Group
PARIS -- Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, today announced that Jean-Baptiste Didier has joined the firm as a Managing Director in its Financial Sponsors Group, based in Paris.
Mr. Didier will lead the firm's financial sponsor coverage ... Show Full Article LOS ANGELES, California, Sept. 4 [Category: BizFinancial Services] -- Houlihan Lokey, an investment bank, issued the following news release: * * * Houlihan Lokey Continues to Expand European Financial Sponsors Coverage Team With Senior Hire in France Jean-Baptiste Didier Joins as a Managing Director in the Financial Sponsors Group PARIS -- Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, today announced that Jean-Baptiste Didier has joined the firm as a Managing Director in its Financial Sponsors Group, based in Paris. Mr. Didier will lead the firm's financial sponsor coverageactivities in France, working closely with Christian Keller, Managing Director and Head of European Private Equity Coverage, and senior colleagues across Houlihan Lokey's global Financial Sponsors Group. His appointment further strengthens the firm's coverage of the French private equity market and builds on Houlihan Lokey's continued investment in the country, following its acquisition of a controlling interest in Audere Partners earlier this year.
Mr. Didier joins Houlihan Lokey from Stifel, where he served as a Managing Director and Head of Healthcare Investment Banking France. Prior to that, he was Head of Sponsor and Infrastructure Coverage France at Citi, advising leading private equity firms and infrastructure investors on a broad range of landmark transactions. Earlier in his career, he advised corporate and financial sponsor clients at J.P. Morgan and Morgan Stanley, building deep expertise across mergers and acquisitions, capital markets, and strategic advisory.
His arrival follows the additions of Managing Directors Martin Rezaie in Germany and Neil Price in the U.K. over the past 12 months, as the firm continues to build out its senior talent across key European markets.
"Mr. Didier has an outstanding track record advising many of France's most prominent private equity firms on complex and high-profile transactions, and his arrival further underscores the exceptional momentum within our Financial Sponsors Group in Europe," said Mr. Keller. "His deep-rooted connectivity across the private equity ecosystem, combined with his nuanced understanding of the French landscape, will be invaluable as we continue to deliver best-in-class advice and solidify our position as the premier middle-market advisor to alternative capital providers in France and across the broader European ecosystem."
"Houlihan Lokey has established a world-class proposition that resonates deeply with the alternative capital ecosystem," said Mr. Didier. "The firm's combination of global reach, deep industry expertise and its client-centric ethos creates a differentiated offering for financial sponsors. I am delighted to join Houlihan Lokey at such an important stage of its growth in France and look forward to working alongside colleagues across Europe and globally to help clients navigate a complex transaction landscape."
Houlihan Lokey is among the leading advisors to alternative capital providers, with its Financial Sponsors Group being one of the largest dedicated teams of any investment bank. The global team comprises more than 35 professionals, including 24 Managing Directors, located across ten countries and manages more than 2,000 relationships worldwide, including private equity firms, credit funds, family offices, and sovereign wealth funds.
***
Original text here: https://hl.com/about-us/newsroom/houlihan-lokey-continues-to-expand-european-financial-sponsors-coverage-team-with-senior-hire-in-france/
* * *
Houlihan Lokey Continues to Expand European Financial Sponsors Coverage Team With Senior Hire in France
Jean-Baptiste Didier Joins as a Managing Director in the Financial Sponsors Group
PARIS -- Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, today announced that Jean-Baptiste Didier has joined the firm as a Managing Director in its Financial Sponsors Group, based in Paris.
Mr. Didier will lead the firm's financial sponsor coverage ... Show Full Article LOS ANGELES, California, Sept. 4 [Category: BizFinancial Services] -- Houlihan Lokey, an investment bank, issued the following news release: * * * Houlihan Lokey Continues to Expand European Financial Sponsors Coverage Team With Senior Hire in France Jean-Baptiste Didier Joins as a Managing Director in the Financial Sponsors Group PARIS -- Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, today announced that Jean-Baptiste Didier has joined the firm as a Managing Director in its Financial Sponsors Group, based in Paris. Mr. Didier will lead the firm's financial sponsor coverageactivities in France, working closely with Christian Keller, Managing Director and Head of European Private Equity Coverage, and senior colleagues across Houlihan Lokey's global Financial Sponsors Group. His appointment further strengthens the firm's coverage of the French private equity market and builds on Houlihan Lokey's continued investment in the country, following its acquisition of a controlling interest in Audere Partners earlier this year.
Mr. Didier joins Houlihan Lokey from Stifel, where he served as a Managing Director and Head of Healthcare Investment Banking France. Prior to that, he was Head of Sponsor and Infrastructure Coverage France at Citi, advising leading private equity firms and infrastructure investors on a broad range of landmark transactions. Earlier in his career, he advised corporate and financial sponsor clients at J.P. Morgan and Morgan Stanley, building deep expertise across mergers and acquisitions, capital markets, and strategic advisory.
His arrival follows the additions of Managing Directors Martin Rezaie in Germany and Neil Price in the U.K. over the past 12 months, as the firm continues to build out its senior talent across key European markets.
"Mr. Didier has an outstanding track record advising many of France's most prominent private equity firms on complex and high-profile transactions, and his arrival further underscores the exceptional momentum within our Financial Sponsors Group in Europe," said Mr. Keller. "His deep-rooted connectivity across the private equity ecosystem, combined with his nuanced understanding of the French landscape, will be invaluable as we continue to deliver best-in-class advice and solidify our position as the premier middle-market advisor to alternative capital providers in France and across the broader European ecosystem."
"Houlihan Lokey has established a world-class proposition that resonates deeply with the alternative capital ecosystem," said Mr. Didier. "The firm's combination of global reach, deep industry expertise and its client-centric ethos creates a differentiated offering for financial sponsors. I am delighted to join Houlihan Lokey at such an important stage of its growth in France and look forward to working alongside colleagues across Europe and globally to help clients navigate a complex transaction landscape."
Houlihan Lokey is among the leading advisors to alternative capital providers, with its Financial Sponsors Group being one of the largest dedicated teams of any investment bank. The global team comprises more than 35 professionals, including 24 Managing Directors, located across ten countries and manages more than 2,000 relationships worldwide, including private equity firms, credit funds, family offices, and sovereign wealth funds.
***
Original text here: https://hl.com/about-us/newsroom/houlihan-lokey-continues-to-expand-european-financial-sponsors-coverage-team-with-senior-hire-in-france/
Frost and Sullivan: Preventive & Predictive Healthcare - Acelerating the Shift From Sick Care to Well Care
SAN ANTONIO, Texas, Sept. 4 -- Frost and Sullivan, a provider of market research and analysis, growth strategy consulting and corporate training services, posted the following news release:
* * *
Preventive & Predictive Healthcare: Acelerating the Shift from Sick Care to Well Care
This blog is based on the analysis titled, "Preventive & Predictive Healthcare: From Sick Care to Well Care," authored by Frost & Sullivan's growth expert, Sukriti Mahna, and lead analyst, Siddharth Dhamija, from the TechVision--Megatrends team.
Executive Summary
Healthcare is undergoing a fundamental transformation ... Show Full Article SAN ANTONIO, Texas, Sept. 4 -- Frost and Sullivan, a provider of market research and analysis, growth strategy consulting and corporate training services, posted the following news release: * * * Preventive & Predictive Healthcare: Acelerating the Shift from Sick Care to Well Care This blog is based on the analysis titled, "Preventive & Predictive Healthcare: From Sick Care to Well Care," authored by Frost & Sullivan's growth expert, Sukriti Mahna, and lead analyst, Siddharth Dhamija, from the TechVision--Megatrends team. Executive Summary Healthcare is undergoing a fundamental transformationfrom treating disease after it occurs to predicting, preventing, and proactively managing health. Driven by artificial intelligence (AI), predictive analytics, digital biomarkers, connected health technologies, and value-based care models, preventive and predictive healthcare is enabling earlier disease detection, continuous health monitoring, and more personalized interventions. As healthcare providers, payers, technology companies, and life sciences organizations invest in intelligent, data-driven care models, new opportunities are emerging to improve patient outcomes, reduce long-term healthcare costs, and build more resilient healthcare ecosystems.
What Is Preventive & Predictive Healthcare?
Preventive and predictive healthcare is a proactive approach to health management that focuses on identifying disease risks early, preventing illness, and supporting long-term wellness through continuous monitoring and personalized care. Unlike traditional healthcare models that primarily respond after symptoms appear, preventive and predictive healthcare combines AI, predictive analytics, digital biomarkers, genomics, wearable technologies, and connected health platforms to anticipate health risks and enable earlier intervention.
This approach shifts healthcare from episodic treatment to continuous, data-driven health management, empowering clinicians with real-time insights while encouraging individuals to take a more active role in managing their health. As healthcare systems worldwide prioritize prevention, value-based care, and digital transformation, preventive and predictive healthcare is becoming a strategic foundation for improving clinical outcomes, enhancing patient experiences, and creating more sustainable healthcare delivery models.
Why Preventive & Predictive Healthcare Is Becoming a Strategic Priority
Healthcare is shifting from treating disease to maintaining long-term health. Rising chronic disease prevalence, aging populations, escalating healthcare costs, and advances in AI and digital health are accelerating investments in preventive care, continuous monitoring, and personalized interventions.
* AI Is Enabling Earlier Disease Prediction: AI is improving early risk detection by analyzing clinical, imaging, genomic, and behavioral data to support faster, more accurate clinical decisions.
* Continuous Health Monitoring Is Becoming the New Standard: Wearables, connected devices, and remote monitoring platforms are enabling real-time health insights, supporting earlier intervention and proactive care.
* Value-based Care Is Accelerating Healthcare Transformation: Healthcare providers are prioritizing prevention, improved patient outcomes, and long-term cost efficiency through personalized, data-driven care models.
Preventive & Predictive Healthcare: From Sick Care to Well Care
Explore how AI, predictive analytics, digital biomarkers, connected health ecosystems, and personalized care models are reshaping healthcare delivery and creating the next generation of growth opportunities.
Download the Complimentary Sample Analysis to discover the technologies, emerging trends, strategic priorities, and innovation opportunities accelerating the shift toward preventive and predictive healthcare.
Frost & Sullivan Perspective
Frost & Sullivan believes preventive and predictive healthcare will become the foundation of next-generation healthcare systems. Organizations that combine AI, connected health technologies, and personalized care into integrated healthcare ecosystems will be better positioned to enable earlier disease prediction, deliver continuous health monitoring, and accelerate value-based care. As digital health ecosystems continue to mature, these capabilities will play a pivotal role in improving patient outcomes, enhancing engagement, and leading the transition from reactive sick care to proactive well care.
Listen to the Growth Podcast to hear Frost & Sullivan experts discuss the future of preventive and predictive healthcare.
Three Megatrends Reshaping Preventive & Predictive Healthcare
1. AI-powered Predictive Intelligence: Artificial intelligence is transforming healthcare by enabling earlier disease prediction, improving diagnostic accuracy, and supporting personalized clinical decision-making through the analysis of multimodal health data.
2. Connected Health and Continuous Monitoring: Wearables, remote patient monitoring, and digital health platforms are enabling continuous health tracking beyond traditional clinical settings, empowering earlier intervention and more proactive patient management.
3. Personalized Well Care: Digital biomarkers, genomics, and predictive analytics are enabling individualized prevention strategies that improve long-term health outcomes while supporting the shift toward value-based healthcare.
Which healthcare megatrends will have the greatest impact on your organization's long-term growth strategy?
* Subscribe to the Growth Opportunity Newsletter for the latest growth opportunities shaping the future of preventive and predictive healthcare.
Emerging Business Models Accelerating Preventive & Predictive Healthcare
The transformation toward preventive and predictive healthcare is reshaping how healthcare organizations create and deliver value. AI, connected health technologies, and digital platforms are enabling new care models that improve patient engagement, support continuous health management, and strengthen value-based healthcare delivery.
Business Model ... How It Creates Value
Preventive Health-as-a-Service (PHaaS) ... Delivers subscription-based health assessments, continuous wellness programs, and personalized preventive care through AI-enabled digital platforms.
Remote Monitoring & Virtual Care ... Combines wearable devices, connected sensors, and telehealth to enable continuous patient monitoring and proactive clinical intervention beyond traditional care settings.
Personalized Health Intelligence ... Integrates AI, predictive analytics, digital biomarkers, and multimodal health data to deliver individualized risk assessments and tailored prevention strategies.
How can your organization leverage emerging healthcare business models to deliver continuous, personalized, and value-based care?
Frost & Sullivan Perspective
Frost & Sullivan believes the future of preventive healthcare will be driven by organizations that transition from delivering episodic medical services to providing continuous, data-driven health management. Business models built around AI, connected care, and personalized health intelligence will create stronger patient relationships, improve outcomes, and unlock sustainable long-term growth.
Companies to Action: Innovators Shaping Preventive & Predictive Healthcare
The transition to preventive and predictive healthcare is being accelerated by companies developing AI-powered diagnostics, digital biomarkers, personalized health intelligence, and continuous monitoring solutions. These innovators are redefining how healthcare organizations predict disease, engage patients, and deliver personalized care.
* InsideTracker: Advancing Personalized Health Intelligence
InsideTracker combines blood biomarker analysis, DNA insights, and lifestyle data to deliver personalized health recommendations that help individuals identify risks early and make informed decisions to improve long-term health.
* Bioniq: Driving Precision Nutrition Through AI
Bioniq leverages AI and biomarker analysis to develop personalized nutritional formulations tailored to an individual's health profile, supporting preventive care and long-term wellness.
* Sonde Health: Transforming Voice into a Digital Biomarker
Sonde Health uses AI-powered voice analysis to identify subtle changes associated with respiratory and mental health conditions, demonstrating the growing potential of non-invasive digital biomarkers for continuous health assessment.
* Canary Speech: Enabling Early Disease Detection Through Speech Analytics
Canary Speech applies AI to analyze vocal biomarkers associated with neurological, cognitive, and behavioral health conditions, enabling earlier intervention and supporting more proactive healthcare delivery.
Growth Opportunities Defining the Future of Preventive & Predictive Healthcare
The transition from reactive sick care to proactive well care is creating new opportunities across the healthcare ecosystem. Advances in AI, digital health, predictive analytics, and connected care are enabling earlier disease detection, continuous health monitoring, and personalized interventions.
AI-driven Early Disease Prediction Platforms: Transforming Healthcare Through Predictive Intelligence
AI-powered platforms are enabling healthcare providers to identify disease risks before symptoms appear by integrating medical imaging, clinical records, genomics, and predictive analytics. These solutions are improving diagnostic accuracy, supporting earlier interventions, and enabling more personalized clinical decision-making across chronic and complex diseases.
Digital Biomarkers and Personalized Health: Advancing Precision Prevention
Digital biomarkers are enabling a new generation of preventive healthcare by combining physiological, behavioral, and molecular data with AI-powered analytics. These insights support earlier disease detection, personalized risk assessment, and precision prevention, helping healthcare organizations deliver more proactive and individualized care.
How will your organization capitalize on AI, connected health ecosystems, and personalized care to lead the transition from sick care to well care?
Future Outlook
The future of preventive and predictive healthcare will be shaped by advances in artificial intelligence (AI), predictive analytics, digital biomarkers, connected health technologies, and personalized care models. As healthcare systems increasingly prioritize prevention, early intervention, and value-based care, these innovations will play a critical role in improving patient outcomes, reducing healthcare costs, and enabling more proactive health management.
According to Frost & Sullivan, organizations that invest early in AI-enabled healthcare platforms, continuous health monitoring, and connected care ecosystems will be better positioned to accelerate the transition from reactive sick care to proactive well care, deliver more personalized patient experiences, and create sustainable long-term growth opportunities.
Download the Complimentary Sample Analysis to explore the technologies, healthcare megatrends, and growth opportunities accelerating the shift from reactive sick care to proactive well care.
Ready to Lead the Transformation? (https://go.frost.com/tgp/tv/pllv_predictivehealthcare?campaign_source=blog&utm_medium=referral&utm_source=blog&utm_campaign=TnV10_TG09_Healthcare_Aug26&utm_content=inline-content&utm_term=blog_PreventiveHealthcare)
Ready to Lead the Transformation?
* Schedule a Growth Strategy Dialog: Align your growth roadmap with Frost & Sullivan's Visionary Growth Pipeline(TM) Dialog.
* Engage with Growth Experts: Co-design AI-enabled, data-driven operating models that scale industry-specific and commercial impact.
* Showcase Your Transformational Leadership: Position your organization as a transformation leader through Frost & Sullivan's Transformational Growth Leadership platform.
* Join the Growth Council: Collaborate with industry leaders shaping the future of your ecosystem.
* Explore Best Practices Recognition: Be recognized for excellence in growth strategy, execution, and customer impact.
* Benchmark Your Industry Positioning on the Frost Radar(TM): Benchmark your growth performance and innovation strength against industry competitors.
* Tell Your Story: Accelerate awareness, engagement, and revenue growth through integrated brand and demand generation strategies.
Connect with our growth experts at transformation.growth@frost.com.
Frequently Asked Questions (FAQs)
1. What is preventive and predictive healthcare?
Preventive and predictive healthcare is a proactive approach to healthcare that focuses on identifying disease risks early, preventing illness, and supporting long-term wellness. By combining artificial intelligence (AI), predictive analytics, digital biomarkers, wearable technologies, and connected health platforms, healthcare providers can enable earlier intervention, continuous monitoring, and more personalized care.
2. How does preventive and predictive healthcare differ from traditional healthcare?
Traditional healthcare primarily focuses on diagnosing and treating diseases after symptoms appear. Preventive and predictive healthcare emphasizes early risk detection, continuous health monitoring, and personalized interventions to reduce disease burden, improve patient outcomes, and support long-term well care.
3. Why is AI important in preventive and predictive healthcare?
AI enables healthcare organizations to analyze large volumes of clinical, imaging, genomic, and behavioral data to identify disease risks earlier and support more accurate clinical decision-making. AI-powered diagnostics and predictive analytics are helping improve early detection, personalize treatment strategies, and enhance healthcare efficiency.
4. What technologies are driving preventive and predictive healthcare?
Key technologies include AI-powered diagnostics, predictive analytics, digital biomarkers, wearable devices, remote patient monitoring, connected health platforms, genomics, and telehealth. Together, these technologies enable continuous health intelligence and more proactive healthcare delivery.
5. What are digital biomarkers, and why are they important?
Digital biomarkers are measurable physiological, behavioral, or biological data collected through wearable devices, smartphones, voice analysis, and connected health technologies. They provide continuous health insights that support earlier disease detection, personalized risk assessment, and more proactive patient management.
6. What industries and organizations benefit from preventive and predictive healthcare?
Preventive and predictive healthcare benefits hospitals, health systems, payers, life sciences companies, medical device manufacturers, digital health providers, employers, and technology companies. These organizations can improve patient outcomes, reduce healthcare costs, and strengthen value-based care through data-driven prevention strategies.
7. What are the biggest growth opportunities in preventive and predictive healthcare?
High-growth opportunities include AI-driven early disease prediction, health monitoring and wearable ecosystems, digital biomarkers, personalized healthcare, remote patient monitoring, and connected health platforms. These areas are accelerating the transition from reactive sick care to proactive well care.
8. What is the future of preventive and predictive healthcare?
The future of preventive and predictive healthcare will be driven by advances in AI, predictive analytics, digital biomarkers, connected health ecosystems, and personalized care models. As healthcare systems increasingly prioritize prevention and value-based care, organizations investing in intelligent, data-driven healthcare solutions will be better positioned to improve health outcomes, enhance patient experiences, and unlock long-term growth opportunities
* * *
Sneha Nair is a Content Innovation Manager at Frost & Sullivan with over a decade of experience shaping strategic narratives that support growth priorities and global thought leadership. She brings strong ownership and clarity to complex insights, working closely with analysts, practice leaders, and commercial teams. At Frost & Sullivan, she leads content strategy and execution across TechVision domains, translating growth into compelling, decision-ready narratives that drive engagement and impact.
* * *
Original text here: https://www.frost.com/growth-opportunity-news/techvision/preventive-predictive-healthcare-acelerating-the-shift-from-sick-care-to-well-care-tnv10_tg09_healthcare_aug26_cim-sn/
[Category: BizConsulting]
* * *
Preventive & Predictive Healthcare: Acelerating the Shift from Sick Care to Well Care
This blog is based on the analysis titled, "Preventive & Predictive Healthcare: From Sick Care to Well Care," authored by Frost & Sullivan's growth expert, Sukriti Mahna, and lead analyst, Siddharth Dhamija, from the TechVision--Megatrends team.
Executive Summary
Healthcare is undergoing a fundamental transformation ... Show Full Article SAN ANTONIO, Texas, Sept. 4 -- Frost and Sullivan, a provider of market research and analysis, growth strategy consulting and corporate training services, posted the following news release: * * * Preventive & Predictive Healthcare: Acelerating the Shift from Sick Care to Well Care This blog is based on the analysis titled, "Preventive & Predictive Healthcare: From Sick Care to Well Care," authored by Frost & Sullivan's growth expert, Sukriti Mahna, and lead analyst, Siddharth Dhamija, from the TechVision--Megatrends team. Executive Summary Healthcare is undergoing a fundamental transformationfrom treating disease after it occurs to predicting, preventing, and proactively managing health. Driven by artificial intelligence (AI), predictive analytics, digital biomarkers, connected health technologies, and value-based care models, preventive and predictive healthcare is enabling earlier disease detection, continuous health monitoring, and more personalized interventions. As healthcare providers, payers, technology companies, and life sciences organizations invest in intelligent, data-driven care models, new opportunities are emerging to improve patient outcomes, reduce long-term healthcare costs, and build more resilient healthcare ecosystems.
What Is Preventive & Predictive Healthcare?
Preventive and predictive healthcare is a proactive approach to health management that focuses on identifying disease risks early, preventing illness, and supporting long-term wellness through continuous monitoring and personalized care. Unlike traditional healthcare models that primarily respond after symptoms appear, preventive and predictive healthcare combines AI, predictive analytics, digital biomarkers, genomics, wearable technologies, and connected health platforms to anticipate health risks and enable earlier intervention.
This approach shifts healthcare from episodic treatment to continuous, data-driven health management, empowering clinicians with real-time insights while encouraging individuals to take a more active role in managing their health. As healthcare systems worldwide prioritize prevention, value-based care, and digital transformation, preventive and predictive healthcare is becoming a strategic foundation for improving clinical outcomes, enhancing patient experiences, and creating more sustainable healthcare delivery models.
Why Preventive & Predictive Healthcare Is Becoming a Strategic Priority
Healthcare is shifting from treating disease to maintaining long-term health. Rising chronic disease prevalence, aging populations, escalating healthcare costs, and advances in AI and digital health are accelerating investments in preventive care, continuous monitoring, and personalized interventions.
* AI Is Enabling Earlier Disease Prediction: AI is improving early risk detection by analyzing clinical, imaging, genomic, and behavioral data to support faster, more accurate clinical decisions.
* Continuous Health Monitoring Is Becoming the New Standard: Wearables, connected devices, and remote monitoring platforms are enabling real-time health insights, supporting earlier intervention and proactive care.
* Value-based Care Is Accelerating Healthcare Transformation: Healthcare providers are prioritizing prevention, improved patient outcomes, and long-term cost efficiency through personalized, data-driven care models.
Preventive & Predictive Healthcare: From Sick Care to Well Care
Explore how AI, predictive analytics, digital biomarkers, connected health ecosystems, and personalized care models are reshaping healthcare delivery and creating the next generation of growth opportunities.
Download the Complimentary Sample Analysis to discover the technologies, emerging trends, strategic priorities, and innovation opportunities accelerating the shift toward preventive and predictive healthcare.
Frost & Sullivan Perspective
Frost & Sullivan believes preventive and predictive healthcare will become the foundation of next-generation healthcare systems. Organizations that combine AI, connected health technologies, and personalized care into integrated healthcare ecosystems will be better positioned to enable earlier disease prediction, deliver continuous health monitoring, and accelerate value-based care. As digital health ecosystems continue to mature, these capabilities will play a pivotal role in improving patient outcomes, enhancing engagement, and leading the transition from reactive sick care to proactive well care.
Listen to the Growth Podcast to hear Frost & Sullivan experts discuss the future of preventive and predictive healthcare.
Three Megatrends Reshaping Preventive & Predictive Healthcare
1. AI-powered Predictive Intelligence: Artificial intelligence is transforming healthcare by enabling earlier disease prediction, improving diagnostic accuracy, and supporting personalized clinical decision-making through the analysis of multimodal health data.
2. Connected Health and Continuous Monitoring: Wearables, remote patient monitoring, and digital health platforms are enabling continuous health tracking beyond traditional clinical settings, empowering earlier intervention and more proactive patient management.
3. Personalized Well Care: Digital biomarkers, genomics, and predictive analytics are enabling individualized prevention strategies that improve long-term health outcomes while supporting the shift toward value-based healthcare.
Which healthcare megatrends will have the greatest impact on your organization's long-term growth strategy?
* Subscribe to the Growth Opportunity Newsletter for the latest growth opportunities shaping the future of preventive and predictive healthcare.
Emerging Business Models Accelerating Preventive & Predictive Healthcare
The transformation toward preventive and predictive healthcare is reshaping how healthcare organizations create and deliver value. AI, connected health technologies, and digital platforms are enabling new care models that improve patient engagement, support continuous health management, and strengthen value-based healthcare delivery.
Business Model ... How It Creates Value
Preventive Health-as-a-Service (PHaaS) ... Delivers subscription-based health assessments, continuous wellness programs, and personalized preventive care through AI-enabled digital platforms.
Remote Monitoring & Virtual Care ... Combines wearable devices, connected sensors, and telehealth to enable continuous patient monitoring and proactive clinical intervention beyond traditional care settings.
Personalized Health Intelligence ... Integrates AI, predictive analytics, digital biomarkers, and multimodal health data to deliver individualized risk assessments and tailored prevention strategies.
How can your organization leverage emerging healthcare business models to deliver continuous, personalized, and value-based care?
Frost & Sullivan Perspective
Frost & Sullivan believes the future of preventive healthcare will be driven by organizations that transition from delivering episodic medical services to providing continuous, data-driven health management. Business models built around AI, connected care, and personalized health intelligence will create stronger patient relationships, improve outcomes, and unlock sustainable long-term growth.
Companies to Action: Innovators Shaping Preventive & Predictive Healthcare
The transition to preventive and predictive healthcare is being accelerated by companies developing AI-powered diagnostics, digital biomarkers, personalized health intelligence, and continuous monitoring solutions. These innovators are redefining how healthcare organizations predict disease, engage patients, and deliver personalized care.
* InsideTracker: Advancing Personalized Health Intelligence
InsideTracker combines blood biomarker analysis, DNA insights, and lifestyle data to deliver personalized health recommendations that help individuals identify risks early and make informed decisions to improve long-term health.
* Bioniq: Driving Precision Nutrition Through AI
Bioniq leverages AI and biomarker analysis to develop personalized nutritional formulations tailored to an individual's health profile, supporting preventive care and long-term wellness.
* Sonde Health: Transforming Voice into a Digital Biomarker
Sonde Health uses AI-powered voice analysis to identify subtle changes associated with respiratory and mental health conditions, demonstrating the growing potential of non-invasive digital biomarkers for continuous health assessment.
* Canary Speech: Enabling Early Disease Detection Through Speech Analytics
Canary Speech applies AI to analyze vocal biomarkers associated with neurological, cognitive, and behavioral health conditions, enabling earlier intervention and supporting more proactive healthcare delivery.
Growth Opportunities Defining the Future of Preventive & Predictive Healthcare
The transition from reactive sick care to proactive well care is creating new opportunities across the healthcare ecosystem. Advances in AI, digital health, predictive analytics, and connected care are enabling earlier disease detection, continuous health monitoring, and personalized interventions.
AI-driven Early Disease Prediction Platforms: Transforming Healthcare Through Predictive Intelligence
AI-powered platforms are enabling healthcare providers to identify disease risks before symptoms appear by integrating medical imaging, clinical records, genomics, and predictive analytics. These solutions are improving diagnostic accuracy, supporting earlier interventions, and enabling more personalized clinical decision-making across chronic and complex diseases.
Digital Biomarkers and Personalized Health: Advancing Precision Prevention
Digital biomarkers are enabling a new generation of preventive healthcare by combining physiological, behavioral, and molecular data with AI-powered analytics. These insights support earlier disease detection, personalized risk assessment, and precision prevention, helping healthcare organizations deliver more proactive and individualized care.
How will your organization capitalize on AI, connected health ecosystems, and personalized care to lead the transition from sick care to well care?
Future Outlook
The future of preventive and predictive healthcare will be shaped by advances in artificial intelligence (AI), predictive analytics, digital biomarkers, connected health technologies, and personalized care models. As healthcare systems increasingly prioritize prevention, early intervention, and value-based care, these innovations will play a critical role in improving patient outcomes, reducing healthcare costs, and enabling more proactive health management.
According to Frost & Sullivan, organizations that invest early in AI-enabled healthcare platforms, continuous health monitoring, and connected care ecosystems will be better positioned to accelerate the transition from reactive sick care to proactive well care, deliver more personalized patient experiences, and create sustainable long-term growth opportunities.
Download the Complimentary Sample Analysis to explore the technologies, healthcare megatrends, and growth opportunities accelerating the shift from reactive sick care to proactive well care.
Ready to Lead the Transformation? (https://go.frost.com/tgp/tv/pllv_predictivehealthcare?campaign_source=blog&utm_medium=referral&utm_source=blog&utm_campaign=TnV10_TG09_Healthcare_Aug26&utm_content=inline-content&utm_term=blog_PreventiveHealthcare)
Ready to Lead the Transformation?
* Schedule a Growth Strategy Dialog: Align your growth roadmap with Frost & Sullivan's Visionary Growth Pipeline(TM) Dialog.
* Engage with Growth Experts: Co-design AI-enabled, data-driven operating models that scale industry-specific and commercial impact.
* Showcase Your Transformational Leadership: Position your organization as a transformation leader through Frost & Sullivan's Transformational Growth Leadership platform.
* Join the Growth Council: Collaborate with industry leaders shaping the future of your ecosystem.
* Explore Best Practices Recognition: Be recognized for excellence in growth strategy, execution, and customer impact.
* Benchmark Your Industry Positioning on the Frost Radar(TM): Benchmark your growth performance and innovation strength against industry competitors.
* Tell Your Story: Accelerate awareness, engagement, and revenue growth through integrated brand and demand generation strategies.
Connect with our growth experts at transformation.growth@frost.com.
Frequently Asked Questions (FAQs)
1. What is preventive and predictive healthcare?
Preventive and predictive healthcare is a proactive approach to healthcare that focuses on identifying disease risks early, preventing illness, and supporting long-term wellness. By combining artificial intelligence (AI), predictive analytics, digital biomarkers, wearable technologies, and connected health platforms, healthcare providers can enable earlier intervention, continuous monitoring, and more personalized care.
2. How does preventive and predictive healthcare differ from traditional healthcare?
Traditional healthcare primarily focuses on diagnosing and treating diseases after symptoms appear. Preventive and predictive healthcare emphasizes early risk detection, continuous health monitoring, and personalized interventions to reduce disease burden, improve patient outcomes, and support long-term well care.
3. Why is AI important in preventive and predictive healthcare?
AI enables healthcare organizations to analyze large volumes of clinical, imaging, genomic, and behavioral data to identify disease risks earlier and support more accurate clinical decision-making. AI-powered diagnostics and predictive analytics are helping improve early detection, personalize treatment strategies, and enhance healthcare efficiency.
4. What technologies are driving preventive and predictive healthcare?
Key technologies include AI-powered diagnostics, predictive analytics, digital biomarkers, wearable devices, remote patient monitoring, connected health platforms, genomics, and telehealth. Together, these technologies enable continuous health intelligence and more proactive healthcare delivery.
5. What are digital biomarkers, and why are they important?
Digital biomarkers are measurable physiological, behavioral, or biological data collected through wearable devices, smartphones, voice analysis, and connected health technologies. They provide continuous health insights that support earlier disease detection, personalized risk assessment, and more proactive patient management.
6. What industries and organizations benefit from preventive and predictive healthcare?
Preventive and predictive healthcare benefits hospitals, health systems, payers, life sciences companies, medical device manufacturers, digital health providers, employers, and technology companies. These organizations can improve patient outcomes, reduce healthcare costs, and strengthen value-based care through data-driven prevention strategies.
7. What are the biggest growth opportunities in preventive and predictive healthcare?
High-growth opportunities include AI-driven early disease prediction, health monitoring and wearable ecosystems, digital biomarkers, personalized healthcare, remote patient monitoring, and connected health platforms. These areas are accelerating the transition from reactive sick care to proactive well care.
8. What is the future of preventive and predictive healthcare?
The future of preventive and predictive healthcare will be driven by advances in AI, predictive analytics, digital biomarkers, connected health ecosystems, and personalized care models. As healthcare systems increasingly prioritize prevention and value-based care, organizations investing in intelligent, data-driven healthcare solutions will be better positioned to improve health outcomes, enhance patient experiences, and unlock long-term growth opportunities
* * *
Sneha Nair is a Content Innovation Manager at Frost & Sullivan with over a decade of experience shaping strategic narratives that support growth priorities and global thought leadership. She brings strong ownership and clarity to complex insights, working closely with analysts, practice leaders, and commercial teams. At Frost & Sullivan, she leads content strategy and execution across TechVision domains, translating growth into compelling, decision-ready narratives that drive engagement and impact.
* * *
Original text here: https://www.frost.com/growth-opportunity-news/techvision/preventive-predictive-healthcare-acelerating-the-shift-from-sick-care-to-well-care-tnv10_tg09_healthcare_aug26_cim-sn/
[Category: BizConsulting]
Deloitte launches Open Model Engineering practice
NEW YORK, Sept. 4 [Category: BizConsulting] -- Deloitte, a provider of audit, consulting, financial advisory and risk management services, presented the following news:
* * *
Deloitte launches Open Model Engineering practice
*
New York, NY, USA, 2 September 2026
Key takeaways
* Deloitte's Open Model Engineering practice is designed to help clients deploy enterprise AI applications with greater flexibility, cost predictability, sovereignty, and enhanced control over their data, intellectual property, model behavior, and inference transparency.
* At the outset, the practice will work with ... Show Full Article NEW YORK, Sept. 4 [Category: BizConsulting] -- Deloitte, a provider of audit, consulting, financial advisory and risk management services, presented the following news: * * * Deloitte launches Open Model Engineering practice * New York, NY, USA, 2 September 2026 Key takeaways * Deloitte's Open Model Engineering practice is designed to help clients deploy enterprise AI applications with greater flexibility, cost predictability, sovereignty, and enhanced control over their data, intellectual property, model behavior, and inference transparency. * At the outset, the practice will work withDeloitte firm clients in North America, Europe, and Asia Pacific developing enterprise AI applications and products built on open-source AI frameworks and open models.
* Deloitte plans to hire, train, and certify forward deployed engineers through fiscal year 2027 to grow the new practice.
Why this matters
Deloitte today announced the launch of its Open Model Engineering practice in Deloitte firms around the globe. The move is an expansion of Deloitte's AI services portfolio, reflecting how enterprises and governments are increasingly evaluating open AI models as a way to gain deployment flexibility, manage cost, and increase choices through a mixture of models. Deloitte's new Open Model Engineering practice aims to help organizations design, engineer, deploy and operate AI solutions using open models and full stack open-source engineering tailored to each client's business requirements, regulatory environment and technology footprint.
"Open models are an increasingly important part of the AI landscape and can complement proprietary AI platforms," says Nitin Mittal, Deloitte Global AI leader. "By helping organizations take a mixed-model approach to building, deploying, and scaling multi-agent systems, we can help optimize technical choices while preserving flexibility across their AI stack and maximizing return on investment."
Building an Open Model Engineering practice around the globe
Deloitte firms are rolling out Open Model Engineering services across multiple geographies to help clients evaluate, adopt, and scale open models alongside their existing AI investments, with an initial focus in North America, Europe and Asia Pacific.
* Enterprises today are navigating four important considerations in AI deployment: flexibility to select the right model and architecture for each workload, predictable cost economics as Agentic AI usage scales, sovereignty over where and how models are deployed, and control over enterprise data, intellectual property (IP), and model behavior with transparency on inference.
* Through Deloitte's Open Model Engineering practice, Deloitte firms can help clients:
* Make model and architecture choices selecting from proprietary models, open models, Agentic platforms, cloud services, and/or on-premises infrastructure;
* Manage token economics by choosing the right model, infrastructure and deployment patterns, resulting in improved return on investment;
* Provide greater flexibility to build AI applications of open models, while further fine-tuning them for geographical, linguistic and cultural context; and
* Gain greater choice over where models run, what data is uploaded, and how competitive advantage is retained by protecting IP and the uniqueness of generated inference.
Agentic AI capabilities powered by NVIDIA Nemotron family of open models
Deloitte's Open Model Engineering practice will initially focus on developing enterprise AI applications built on NVIDIA Nemotron open models and NIM microservices. Deloitte firms will also help clients build Sovereign AI stacks using open-source AI frameworks, fine tune open models, and enhance cyber defenses with open harnesses.
"Enterprises need both open and proprietary models for different workloads," says Kari Briski, vice president of Generative AI at NVIDIA. "Deloitte's Open Model Engineering practice, built on NVIDIA Nemotron models, gives developers greater control over enterprise data and proprietary information while enabling secure, responsible deployment of Agentic AI."
As part of this practice, Deloitte firms will leverage the Zora AI(tm) digital workforce platform, with agentic harness capabilities built on NVIDIA Nemotron open models and NIM. This gives clients a path to deploy, continuously optimize and govern AI agents using open models within their own environments.
Investing in talent: Forward deployed engineers
Deloitte plans to hire, train, and certify forward deployed engineers globally certified in open models. These specialists will work directly alongside Deloitte firm clients to implement open model solutions and will serve as the operational foundation of the new practice.
Click here for more information on Deloitte's engineering capabilities.
***
Original text here: https://www.deloitte.com/global/en/about/press-room/deloitte-launches-open-model-engineering-practice.html
* * *
Deloitte launches Open Model Engineering practice
*
New York, NY, USA, 2 September 2026
Key takeaways
* Deloitte's Open Model Engineering practice is designed to help clients deploy enterprise AI applications with greater flexibility, cost predictability, sovereignty, and enhanced control over their data, intellectual property, model behavior, and inference transparency.
* At the outset, the practice will work with ... Show Full Article NEW YORK, Sept. 4 [Category: BizConsulting] -- Deloitte, a provider of audit, consulting, financial advisory and risk management services, presented the following news: * * * Deloitte launches Open Model Engineering practice * New York, NY, USA, 2 September 2026 Key takeaways * Deloitte's Open Model Engineering practice is designed to help clients deploy enterprise AI applications with greater flexibility, cost predictability, sovereignty, and enhanced control over their data, intellectual property, model behavior, and inference transparency. * At the outset, the practice will work withDeloitte firm clients in North America, Europe, and Asia Pacific developing enterprise AI applications and products built on open-source AI frameworks and open models.
* Deloitte plans to hire, train, and certify forward deployed engineers through fiscal year 2027 to grow the new practice.
Why this matters
Deloitte today announced the launch of its Open Model Engineering practice in Deloitte firms around the globe. The move is an expansion of Deloitte's AI services portfolio, reflecting how enterprises and governments are increasingly evaluating open AI models as a way to gain deployment flexibility, manage cost, and increase choices through a mixture of models. Deloitte's new Open Model Engineering practice aims to help organizations design, engineer, deploy and operate AI solutions using open models and full stack open-source engineering tailored to each client's business requirements, regulatory environment and technology footprint.
"Open models are an increasingly important part of the AI landscape and can complement proprietary AI platforms," says Nitin Mittal, Deloitte Global AI leader. "By helping organizations take a mixed-model approach to building, deploying, and scaling multi-agent systems, we can help optimize technical choices while preserving flexibility across their AI stack and maximizing return on investment."
Building an Open Model Engineering practice around the globe
Deloitte firms are rolling out Open Model Engineering services across multiple geographies to help clients evaluate, adopt, and scale open models alongside their existing AI investments, with an initial focus in North America, Europe and Asia Pacific.
* Enterprises today are navigating four important considerations in AI deployment: flexibility to select the right model and architecture for each workload, predictable cost economics as Agentic AI usage scales, sovereignty over where and how models are deployed, and control over enterprise data, intellectual property (IP), and model behavior with transparency on inference.
* Through Deloitte's Open Model Engineering practice, Deloitte firms can help clients:
* Make model and architecture choices selecting from proprietary models, open models, Agentic platforms, cloud services, and/or on-premises infrastructure;
* Manage token economics by choosing the right model, infrastructure and deployment patterns, resulting in improved return on investment;
* Provide greater flexibility to build AI applications of open models, while further fine-tuning them for geographical, linguistic and cultural context; and
* Gain greater choice over where models run, what data is uploaded, and how competitive advantage is retained by protecting IP and the uniqueness of generated inference.
Agentic AI capabilities powered by NVIDIA Nemotron family of open models
Deloitte's Open Model Engineering practice will initially focus on developing enterprise AI applications built on NVIDIA Nemotron open models and NIM microservices. Deloitte firms will also help clients build Sovereign AI stacks using open-source AI frameworks, fine tune open models, and enhance cyber defenses with open harnesses.
"Enterprises need both open and proprietary models for different workloads," says Kari Briski, vice president of Generative AI at NVIDIA. "Deloitte's Open Model Engineering practice, built on NVIDIA Nemotron models, gives developers greater control over enterprise data and proprietary information while enabling secure, responsible deployment of Agentic AI."
As part of this practice, Deloitte firms will leverage the Zora AI(tm) digital workforce platform, with agentic harness capabilities built on NVIDIA Nemotron open models and NIM. This gives clients a path to deploy, continuously optimize and govern AI agents using open models within their own environments.
Investing in talent: Forward deployed engineers
Deloitte plans to hire, train, and certify forward deployed engineers globally certified in open models. These specialists will work directly alongside Deloitte firm clients to implement open model solutions and will serve as the operational foundation of the new practice.
Click here for more information on Deloitte's engineering capabilities.
***
Original text here: https://www.deloitte.com/global/en/about/press-room/deloitte-launches-open-model-engineering-practice.html
Cotality : Institutional Investors Pullback Ahead of New Housing Restrictions
IRVINE, California, Sept. 4 (TNSxrep) -- Cotality (formerly CoreLogic) issued the following news release on Sept. 3, 2026:
* * *
Institutional investors pullback ahead of new housing restrictions
Cotality, a leading global property information, analytics, and data-enabled solutions provider, today released its latest update on investor activity in the U.S. housing market.
Investors accounted for 27% of all U.S. single-family home purchases from March to June 2026, down slightly from 28% at the close of the first quarter.
This modest decline follows standard seasonal patterns as owner-occupied ... Show Full Article IRVINE, California, Sept. 4 (TNSxrep) -- Cotality (formerly CoreLogic) issued the following news release on Sept. 3, 2026: * * * Institutional investors pullback ahead of new housing restrictions Cotality, a leading global property information, analytics, and data-enabled solutions provider, today released its latest update on investor activity in the U.S. housing market. Investors accounted for 27% of all U.S. single-family home purchases from March to June 2026, down slightly from 28% at the close of the first quarter. This modest decline follows standard seasonal patterns as owner-occupiedbuyers become more active during the summer months. Despite the slight dip, investors maintain an outsized market presence relative to historical norms, remaining well above the sub-20% levels typical of the 2010s.
"The investor share dropped in Q2 2026, but that is par for the course in the summer," said Thom Malone, Principal Economist at Cotality. "The more compelling story lies in overall volume. Investors executed roughly 40,000 fewer purchases compared to Q2 2025, with mega investors accounting for about 10,000 of that decline. That represents a significant drop given their small market presence, suggesting that proposed restrictions on institutional investors had an immediate chilling effect. The true test will occur in Q3, now that the legislative framework and exemptions are finalized. We will see whether this was a permanent retreat or just a pause while investors waited for a clear path forward."
* * *
CHART: Share of home purchases made by investors by month, January 2018 - June 2026
* * *
That 40,000-unit drop brought total Q2 investor acquisitions down to 273,000--a decline sharper than the 70,000-unit pullback seen among owner-occupied buyers, who hold double the market share.
When benchmarked against Q2 2020-2022 averages, investor transactions were down 12%, compared to a much steeper 40% deficit for owner-occupants.
* * *
CHART: Monthly home purchases made by investors and non-investors1, January 2018 - June 2026
* * *
Legislative impacts and investor tiers
The 21st Century Road to Housing Act--which restricts single-family property acquisitions for entities owning 350 or more homes--was signed into law on July 11, 2026. However, market behavior reflected the policy change as early as January when the measure was first introduced:
* Mega Investors (1,000+ properties): Averaged ~4,500 monthly purchases in Q1 2026, marking a 40% decline compared to Q1 2025.
* Large Investors (100-999 properties): Acquisition volume fell by 21% year-over-year.
* Medium Investors (10-99 properties): Purchases contracted by 17%.
* Small Investors (3-9 properties): Experienced minimal disruption, with transaction volume dipping just 3%.
Q3 will serve as the baseline for evaluating the law's long-term impact. Clearer guidance surrounding statutory exemptions--such as inter-investor transfers and properties that receive substantial improvements--may prompt institutional capital to re-enter the market.
* * *
CHART: Share of investor purchases by investor size, January 2018 - June 2026
* * *
Geographic trends: Population growth and regulatory drivers
Investor deployment is closely aligned with high-growth metropolitan statistical areas (MSAs) where strong demographic trends support ongoing rental demand.
Year-to-date, Dallas, Houston, and Atlanta rank highest in both investor and non-investor purchases, with Phoenix and Los Angeles rounding out the top five. When looking at investor share, the top five states are Georgia, California, New Mexico, Kansas, and Texas.
California is the notable exception to the population-growth pattern. Despite flat overall population growth, investor interest remains elevated. This is probably driven by municipal mandates that expedite the approval of Accessory Dwelling Units (ADUs), which create opportunities for expansion and value-add strategies.
* * *
CHART: Top 20 MSAs by total investor purchases, January-June 2026
CHART: Investor share by state, January - June 2026
* * *
Market outlook
While second-quarter market share changes followed historical seasonality, broader structural shifts suggest the market will change for the rest of 2026. Clearer regulations may bring institutional investors back in Q3, while private equity firms might explore other asset types.
In both cases, smaller local investors are ready to take available investments. Due to ongoing affordability issues, strong demand for rentals ensures that investors at all levels will play an important role in market liquidity.
Methodology
The Cotality Investor Purchase Indicator defines an investor as a buyer that owns three or more properties. Small investors are defined as those with fewer than 10 properties, medium investors as those with fewer than 100, large investors as those with fewer than 1,000, and mega investors as those with more than 1,000. It is an investor purchase indicator, rather than an investment purchase indicator, meaning that it identifies purchases made by investors but makes no judgment about how the property will be used. For this analysis, only arm's-length purchases of single-family homes (detached houses and townhomes) are considered.
* * *
About Cotality
Cotality accelerates data, insights, and workflows across the property ecosystem to enable industry professionals to surpass their ambitions and impact society. With billions of real-time data signals across the life cycle of a property, we unearth hidden risks and transformative opportunities for agents, lenders, carriers, and innovators. Get to know us at www.cotality.com.
* * *
Original text here: https://www.cotality.com/press-releases/investor-report-q2-2026
[Category: BizReal Estate]
* * *
Institutional investors pullback ahead of new housing restrictions
Cotality, a leading global property information, analytics, and data-enabled solutions provider, today released its latest update on investor activity in the U.S. housing market.
Investors accounted for 27% of all U.S. single-family home purchases from March to June 2026, down slightly from 28% at the close of the first quarter.
This modest decline follows standard seasonal patterns as owner-occupied ... Show Full Article IRVINE, California, Sept. 4 (TNSxrep) -- Cotality (formerly CoreLogic) issued the following news release on Sept. 3, 2026: * * * Institutional investors pullback ahead of new housing restrictions Cotality, a leading global property information, analytics, and data-enabled solutions provider, today released its latest update on investor activity in the U.S. housing market. Investors accounted for 27% of all U.S. single-family home purchases from March to June 2026, down slightly from 28% at the close of the first quarter. This modest decline follows standard seasonal patterns as owner-occupiedbuyers become more active during the summer months. Despite the slight dip, investors maintain an outsized market presence relative to historical norms, remaining well above the sub-20% levels typical of the 2010s.
"The investor share dropped in Q2 2026, but that is par for the course in the summer," said Thom Malone, Principal Economist at Cotality. "The more compelling story lies in overall volume. Investors executed roughly 40,000 fewer purchases compared to Q2 2025, with mega investors accounting for about 10,000 of that decline. That represents a significant drop given their small market presence, suggesting that proposed restrictions on institutional investors had an immediate chilling effect. The true test will occur in Q3, now that the legislative framework and exemptions are finalized. We will see whether this was a permanent retreat or just a pause while investors waited for a clear path forward."
* * *
CHART: Share of home purchases made by investors by month, January 2018 - June 2026
* * *
That 40,000-unit drop brought total Q2 investor acquisitions down to 273,000--a decline sharper than the 70,000-unit pullback seen among owner-occupied buyers, who hold double the market share.
When benchmarked against Q2 2020-2022 averages, investor transactions were down 12%, compared to a much steeper 40% deficit for owner-occupants.
* * *
CHART: Monthly home purchases made by investors and non-investors1, January 2018 - June 2026
* * *
Legislative impacts and investor tiers
The 21st Century Road to Housing Act--which restricts single-family property acquisitions for entities owning 350 or more homes--was signed into law on July 11, 2026. However, market behavior reflected the policy change as early as January when the measure was first introduced:
* Mega Investors (1,000+ properties): Averaged ~4,500 monthly purchases in Q1 2026, marking a 40% decline compared to Q1 2025.
* Large Investors (100-999 properties): Acquisition volume fell by 21% year-over-year.
* Medium Investors (10-99 properties): Purchases contracted by 17%.
* Small Investors (3-9 properties): Experienced minimal disruption, with transaction volume dipping just 3%.
Q3 will serve as the baseline for evaluating the law's long-term impact. Clearer guidance surrounding statutory exemptions--such as inter-investor transfers and properties that receive substantial improvements--may prompt institutional capital to re-enter the market.
* * *
CHART: Share of investor purchases by investor size, January 2018 - June 2026
* * *
Geographic trends: Population growth and regulatory drivers
Investor deployment is closely aligned with high-growth metropolitan statistical areas (MSAs) where strong demographic trends support ongoing rental demand.
Year-to-date, Dallas, Houston, and Atlanta rank highest in both investor and non-investor purchases, with Phoenix and Los Angeles rounding out the top five. When looking at investor share, the top five states are Georgia, California, New Mexico, Kansas, and Texas.
California is the notable exception to the population-growth pattern. Despite flat overall population growth, investor interest remains elevated. This is probably driven by municipal mandates that expedite the approval of Accessory Dwelling Units (ADUs), which create opportunities for expansion and value-add strategies.
* * *
CHART: Top 20 MSAs by total investor purchases, January-June 2026
CHART: Investor share by state, January - June 2026
* * *
Market outlook
While second-quarter market share changes followed historical seasonality, broader structural shifts suggest the market will change for the rest of 2026. Clearer regulations may bring institutional investors back in Q3, while private equity firms might explore other asset types.
In both cases, smaller local investors are ready to take available investments. Due to ongoing affordability issues, strong demand for rentals ensures that investors at all levels will play an important role in market liquidity.
Methodology
The Cotality Investor Purchase Indicator defines an investor as a buyer that owns three or more properties. Small investors are defined as those with fewer than 10 properties, medium investors as those with fewer than 100, large investors as those with fewer than 1,000, and mega investors as those with more than 1,000. It is an investor purchase indicator, rather than an investment purchase indicator, meaning that it identifies purchases made by investors but makes no judgment about how the property will be used. For this analysis, only arm's-length purchases of single-family homes (detached houses and townhomes) are considered.
* * *
About Cotality
Cotality accelerates data, insights, and workflows across the property ecosystem to enable industry professionals to surpass their ambitions and impact society. With billions of real-time data signals across the life cycle of a property, we unearth hidden risks and transformative opportunities for agents, lenders, carriers, and innovators. Get to know us at www.cotality.com.
* * *
Original text here: https://www.cotality.com/press-releases/investor-report-q2-2026
[Category: BizReal Estate]